The role of gene expression profiling in early-stage non-small cell lung cancer

Journal of Thoracic Disease

Volumn 2, Issue 2, 2010, Pages 89-99

  Shao, Wenlong ^a,b,c   Wang, Daoyuan ^b,c   He, Jianxing ^a,b,c  

^a GUANGDONG PROVINCIAL PEOPLE'S HOSPITAL   (China)

^b GUANGZHOU MEDICAL UNIVERSITY   (China)

^c GUANGZHOU MEDICAL UNIVERSITY   (China)

Author keywords

Gene expression profiling; Non small cell lung cancer; Prognostic biomarker

Indexed keywords

EID: 80052713103     PISSN: 20721439     EISSN: 20776624     Source Type: Journal    
DOI: None     Document Type: Review

References (68)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin 2007;57:43-66.
2. Ponn RB, Lo Cicero J III, Daly BDT. Surgical treatment of non small cell lung cancer. In: Shields TW, Lo Cicero J III, Ponn R, Rusch VW, Editors. General Thoracic Surgery, 6th ed. Philadelphia: Lippincott Williams & Wilkins; 2005. p. 1548-87.
3. Wright G, Manser RL, Byrnes G, Hart D, Campbell DA. Surgery for early-stage non-small cell lung cancer: systematic review and metaanalysis of randomised controlled trials. Thorax 2006;61:597-603.
4. Strauss GM. Adjuvant chemotherapy of lung cancer: methodologic issues and therapeutic advances. Hematol Oncol Clin North Am 2005;19:263-81.
5. Nesbitt JC, Putnam JB Jr, Walsh GL, Roth JA, Mountain CF. Survival in early stage non-small cell lung cancer. Ann Thorac Surg 1995;60:466-72.
6. Hoffman PC, Mauer A M, Vokes EE. Lung cancer. Lancet 2000;355:479-85. [Erratum, Lancet 2000;355:1280.]
7. Hoang T, Xu R, Schiller JH, Bonomi P, Johnson DH. Clinical model to predict survival in chemonaïve patients with advanced nonsmall-cell lung cancer treated with third-generation chemotherapy regimens based on eastern cooperative oncology group data. J Clin Oncol 2005;23:175-83.
8. Forrest LM, McMillan DC, McArdle CS, Angerson WT, Dagg K, Scott HR. A prospective longitudinal study of performance status, an inflammation-based score (GPS) and survival in patients with inoperable non-small-cell lung cancer. Br J Cancer 2005;92:1834-6.
9. Brundage MD, Davies D, Mackillop WJ. Prognostic factors in non-small cell lung cancer: a decade of progress. Chest 2002;122:1037-57.
10. Meyerson M, Carbone DP. Genomic and proteomic profiling of lung cancers: lung cancer classification in the age of targeted therapy. J Clin Oncol 2005;23:3219-26.
11. Custodio AB, González-Larriba JL, Bobokova J, Calles A, Alvarez R, Cuadrado E, et al. Prognostic and predictive markers of benefit from adjuvant chemotherapy in early-stage non-small cell lung cancer. J Thorac Oncol 2009;4:891-910.
12. Ludwig JA, Weinstein JN. Biomarkers in cancer staging, prognosis and treatment selection. Nat Rev Cancer 2005;5:845-56.
13. Chen HY, Yu SL, Chen CH, Chang GC, Chen CY, Yuan A, et al. A five-gene signature and clinical outcome in non-small-cell lung cancer. N Engl J Med 2007;356:11-20.
14. Endoh H, Tomida S, Yatabe Y, Konishi H, Osada H, Tajima K, et al. Prognostic model of pulmonary adenocarcinoma by expression profiling of eight genes as determined by quantitative real-time reverse transcriptase polymerase chain reaction. J Clin Oncol 2004;22:811-9.
15. Potti A, Mukherjee S, Petersen R, Dressman HK, Bild A, Koontz J, et al. A genomic strategy to refine prognosis in early-stage nonsmall-cell lung cancer. N Engl J Med 2006;355:570-80.
16. Coussens LM, Werb Z. Inflammation and cancer. Nature 2002; 420:860-7.
17. Jones PA, Baylin SB. The epigenomics of cancer. Cell 2007; 128:683-92.
18. Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature 2008;454:436-44.
19. Chin L, Gray JW. Translating insights from the cancer genome into clinical practice. Nature 2008; 452:553-63.
20. Schena M, Shalon D, Davis RW, Brown PO. Quantitative monitoring of gene expression patterns with a complementary DNA microarray. Science 1995;270:467-70.
21. Lashkari DA, DeRisi JL, McCusker JH, Namath AF, Gentile C, Hwang SY, et al. Yeast microarrays for genome wide parallel genetic and gene expression analysis. Proc Natl Acad Sci U S A 1997; 94:13057-62.
22. Ramaswamy S. Translating cancer genomics into clinical oncology. N Engl J Med 2004; 350:1814-6.
23. Paik S, Kim CY, Song YK, Kim WS. Tech nology insight: Application of molecular techniques to formalin-fixed paraffinembedded tissues from breast cancer. Nat Clin Pract Oncol 2005;2:246-54.
24. Ransohoff DF. How to improve reliability and efficiency of research about molecular markers: roles of phases, guidelines, and study design. J Clin Epidemiol 2007; 60:1205-19.
25. Kratz JR, Jablons DM. Genomic prognostic models in early-stage lung cancer. Clin Lung Cancer 2009;10:151-7.
26. Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem cells. Nature 2001;414:105-11.
27. Heguy A, O'Connor TP, Luettich K, Worgall S, Cieciuch A, Harvey B-G, et al. Gene expression profiling of human alveolar macrophages of phenotypically normal smokers and nonsmokers reveals a previously unrecognized subset of genes modulated by cigarette smoking. J Mol Med 2006;84:318.
28. Borczuk AC, Gorenstein L, Walter KL, Assaad AA, Wang L, Powell CA. Non-small-cell lung cancer molecular signatures recapitulate lung developmental pathways. Am J Pathol 2003;163:1949-60.
29. Glinsky GV, Berezovska O, Glinskii AB. Microarray analysis identifies a death-from-cancer signature predicting therapy failure in patients with multiple types of cancer. J Clin Invest 2005;115:1503-21.
30. Winton T, Livingston R, Johnson D, Rigas J, Johnston M, Butts C, et al. Vinorelbine plus Cisplatin vs. Observation in resected nonsmall-cell lung cancer. N Engl J Med 2005;352:2589-97.
31. Tsao MS, Zhu C, Ding K, Strumpf D, Pintilie M, Meyerson M, et al. A 15-gene expression signature prognostic for survival and predictive for adjuvant chemotherapy benefit in JBR. 10 patients. J Clin Oncol 2008;26(supp):abstr 7510.
32. Staunton JE, Slonim DK, Coller HA, Tamayo P, Angelo MJ, Park J, et al. Chemosensitivity prediction by transcriptional profiling. Proc Natl Acad Sci U S A 2001;98:10787-92.
33. Grever MR, Schepartz SA, Chabner BA. The National Cancer Institute: cancer drug discovery and development program. Semin Oncol 1992; 19:622-38.
34. Stinson SF, Alley MC, Kopp WC, Fiebig HH, Mullendore LA, Pittman AF, et al. Morphological and immunocytochemical characteristics of human tumor cell lines for use in a diseaseoriented anticancer drug screen. Anticancer Res 1992;12:1035-53.
35. Potti A, Dressman HK, Bild A, Riedel RF, Chan G, Sayer R, et al. Genomic signatures to guide the use of chemotherapeutics. Nat Med 2006;12:1294-300. Epub 2006 Oct 22.
36. Beane J, Spira A, Lenburg M E. Clinical impact of highthroughput gene expression studies in lung cancer. J Thorac Oncol 2009;4:109-18.
37. Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004;304:1497-500.
38. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005; 353:123-32.
39. Rosell R, Taron M, Sanchez JJ, Paz-Ares L. Setting the benchmark for tailoring treatment with EGFR tyrosine kinase inhibitors. Future Oncol 2007; 3:277-83.
40. O'Byrne KJ, Danson S, Dunlop D, Botwood N, Taguchi F, Carbone D, et al. Combination therapy with gefitinib and rofecoxib in patients with platinum-pretreated relapsed non small-cell lung cancer. J Clin Oncol 2007; 25:3266-73.
41. Okano T, Kondo T, Fujii K, Nishimura T, Takano T, Ohe Y, et al. Proteomic signature corresponding to the response to gefitinib (Iressa, ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor in lung adenocarcinoma. Clin Cancer Res 2007;13:799-805.
42. Altorki N, Lane ME, Bauer T, Lee PC, Guarino MJ, Pass H, et al. Phase II proof-of-concept study of pazopanib monotherapy in treatment-naive patients with stage I/II resectable non-small-cell lung cancer. J Clin Oncol 2010;28:3131-7. Epub 2010 Jun 1.
43. Nikolinakos PG, Altorki N, Yankelevitz D, Tran HT, Yan S, Rajagopalan D, et al. Plasma cytokine and angiogenic factor profiling identifies markers associated with tumor shrinkage in early-stage non-small cell lung cancer patients treated with pazopanib. Cancer Res 2010;70:2171-9. Epub 2010 Mar 9.
44. Tomida S, Koshikawa K, Yatabe Y, Harano T, Ogura N, Mitsudomi T, et al. Gene expression-based, i nd ividu ali zed outcome prediction for surgically treated lung cancer patients. Oncogene 2004;23:5360-70.
45. Lau SK, Boutros PC, Pintilie M, Blackhall FH, Zhu CQ, Strumpf D, et al. Three-gene prognostic classifier for early-stage non small-cell lung cancer. J Clin Oncol 2007;25:5562-9.
46. Bianchi F, Nuciforo P, Vecchi M, Bernard L, Tizzoni L, Marchetti A, et al. Survival prediction of stage I lung adenocarcinomas by expression of 10 genes. J Clin Invest 2007;117:3436-44.
47. Seike M, Yanaihara N, Bowman ED, Zanetti KA, Budhu A, Kumamoto K, et al. Use of a cytokine gene expression signature in lung adenocarcinoma and the surrounding tissue as a prognostic classifier. J Natl Cancer Inst 2007;99:1257-69.
48. Reed CE, Graham A, Hoda RS, Khoor A, Garrett-Mayer E, Wallace MB, et al. A simple two-gene prognostic model for adenocarcinoma of the lung. J Thorac Cardiovasc Surg 2008;135:627-34.
49. Skrzypski M, Jassem E, Taron M, Sanchez JJ, Mendez P, Rzyman W, et al. Three-gene expression signature predicts survival in early-stage squamous cell carcinoma of the lung. Clin Cancer Res 2008;14:4794-9.
50. Raz DJ, Ray MR, Kim JY, He B, Taron M, Skrzypski M, et al. A multigene assay is prognostic of survival in patients with earlystage lung adenocarcinoma. Clin Cancer Res 2008;14:5565-70.
51. Beer DG, Kardia SL, Huang CC, Giordano TJ, Levin AM, Misek DE, et al. Gene-expression profiles predict survival of patients with lung adenocarcinoma. Nat Med 2002;8:816-24. Epub 2002 Jul 15.
52. Potti A, Mukherjee S, Petersen R, Dressman HK, Bild A, Koontz J, et al. A genomic strategy to refine prognosis in early-stage nonsmall-cell lung cancer. N Engl J Med 2006;355:570-80.
53. Yu H, Jove R. The STATs of cancer-new molecular targets come on age. Nat Rev Cancer 2004;4:97-105.
54. Kumar A, Commane M, Flickinger TW, Horvath CM, Stark GR. Defective TNF-alpha-induced apoptosis in STAT1-null cells due to low constitutive levels of caspases. Science 1997;278:1630-2.
55. Rehli M, Krause SW, Schwarzfischer L, Kreutz M, Andreesen R. Molecular cloning of a novel macrophage maturation-associated transcript encoding a protein with several potential transmembrane domains. Biochem Biophys Res Commun 1995;217:661-7.
56. Chen JJ, Lin YC, Yao PL, Yuan A, Chen HY, Shun CT, et al. Tumor-associated macrophages: the double-edged sword in cancer progression. J Clin Oncol 2005;23:953-64.
57. Furukawa T, Sunamura M, Motoi F, Matsuno S, Horii A. Potential tumor suppressive pathway involving DUSP6/MKP-3 in pancreatic cancer. Am J Pathol 2003;162:1807-15.
58. Müller-Tidow C, Diederichs S, Bulk E, Pohle T, Steffen B, Schwäble J, et al. Identification of metastasis-associated receptor tyrosine kinases in non-small cell lung cancer. Cancer Res 2005;65:1778-82.
59. Zamoyska R, Basson A, Filby A, Legname G, Lovatt M, Seddon B. The influence of the src-family kinases, on T cell differentiation, survival and activation. Immunol Rev 2003;191:107-18.
60. Mahabeleshwar GH, Kundu GC. Tyrosine Kinase p56lck regulates cell motility and nuclear factor kappa B-mediated secretion of urokinase ty pe plasminogen activator through tyrosine phosphorylation of IkappaBalpha following hipoxia/reoxygenation. J Biol Chem 2003;278:52598-612.
61. Mahabeleshwar GH, Das R, Kundu GC. Tyrosine Kinase, p56lckinduced cell motility, and urokinase-type plasminogen activator secretion involve activation of epidermal growth factor receptor/extracellular regulated kinase pathways. J Biol Chem 2004;279:9733-42.
62. Roepman P, Jassem J, Smit EF, Muley T, Niklinski J, van de Velde T, et al. An immune response enriched 72-gene prognostic profile for early-stage non-small-cell lung cancer. Clin Cancer Res 2009;15:284-90.
63. Guo L, Ma Y, Ward R, Castranova V, Shi X, Qian Y. Constructing molecula r cla ssif ier s for the accur ate prognosis of lung adenocarcinoma. Clin Cancer Res 2006;12:3344-54.
64. Lu Y, Lemon W, Liu PY, Yi Y, Morrison C, Yang P, et al. A gene expression signature predicts survival of patients with stage I nonsmall cell lung cancer. PLoS Med 2006;3:e467.
65. Ein-Dor L, Zuk O, Domany E. Thousands of samples are needed to generate a robust gene list for predicting outcome in cancer. Proc Natl Acad Sci USA 2006;103:5923-8.
66. Bachtiary B, Boutros PC, Pintilie M, Shi W, Bastianutto C, Li JH, et al. Gene expression profiling in cervical cancer: An exploration of intratumor heterogeneity. Clin Cancer Res 2006;12:5632-40.
67. Blackhall FH, Pintilie M, Wigle DA, Jurisica I, Liu N, Radulovich N, et al. Stability and heterogeneity of expression profiles in lung cancer specimens harvested following surgical resection. Neoplasia 2004;6:761-7.
68. Boutros PC, Lau SK, Pintilie M, Liu N, Shepherd FA, Der SD, et al. Prognostic gene signatures for non-small-cell lung cancer. Proc Natl Acad Sci U S A 2009;106:2824-8.